Who are MVA-BN vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Smallpox and Mpox Vaccine, MMR followed by YF, Measles Mumps and Rubella Vaccine, Measles-Rubella (MR) Vaccine, Measles-Mumps-Rubella, varicella zoster virus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mva-bn-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MVA-BN vaccine — Competitive Intelligence Brief

MVA-BN vaccine (MVA-BN vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated viral vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated viral vaccine Monkeypox virus antigens (vaccinia virus-vectored) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MVA-BN vaccine (MVA-BN vaccine) — National Institute of Allergy and Infectious Diseases (NIAID). MVA-BN is a live attenuated vaccinia virus vaccine that stimulates immune responses against monkeypox virus antigens to provide protection against mpox infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MVA-BN vaccine TARGET	MVA-BN vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Live attenuated viral vaccine	Monkeypox virus antigens (vaccinia virus-vectored)
Smallpox and Mpox Vaccine	Smallpox and Mpox Vaccine	SIGA Technologies	marketed	Live attenuated viral vaccine / Recombinant viral vaccine
MMR followed by YF	MMR followed by YF	Alba Maria Ropero	marketed	Live attenuated viral vaccine combination
Measles Mumps and Rubella Vaccine	Measles Mumps and Rubella Vaccine	Sanofi	marketed	Live attenuated viral vaccine
Measles-Rubella (MR) Vaccine	Measles-Rubella (MR) Vaccine	PT Bio Farma	marketed	Live attenuated viral vaccine
Measles-Mumps-Rubella	Measles-Mumps-Rubella	Hospital Clinic of Barcelona	marketed	Live attenuated viral vaccine
varicella zoster virus	varicella zoster virus	AstraZeneca	marketed	Live attenuated viral vaccine	Varicella zoster virus envelope glycoproteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated viral vaccine class)

Jean-Pierre Van geertruyden · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Centers for Disease Control and Prevention · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hospital Clinic of Barcelona · 1 drug in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 1 drug in this class
Institute of Tropical Medicine, Belgium · 1 drug in this class
International Vaccine Institute · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MVA-BN vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/mva-bn-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab